Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
about
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtypeSimultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms.Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's MacroglobulinemiaNew Therapeutic Approaches for Waldenstrom MacroglobulinemiaNovel agents in Waldenström macroglobulinemia.Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopeniaNovel agents in Waldenstrom Macroglobulinemia.Follicular lymphoma: today's treatments and tomorrow's targets.Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma.Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L.Therapy-related myeloid leukemia.Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy.A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records.A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
P2860
Q30435188-6D65AF5C-7F1D-4F2D-A273-D3AF91F22433Q33711127-4B812880-A606-4FF7-81AE-71C77A0D8F84Q34488720-C039F9D1-6C36-4ABC-ADA0-696E81EC6A48Q34519513-45217098-1608-45BD-82A3-2B9A9CE752FAQ34870833-D87C7371-A0AE-42E6-AA14-045F1CEF0913Q35153656-BC741B44-46B9-4B1E-A78D-752BBA907782Q35176177-B0251657-F5F8-4FC8-9CCD-9F20F2D13E43Q35429544-706F3F0A-72DB-470D-9944-7C75D7324C0FQ35625192-EFE4B61F-9223-4E26-B114-7D199113DDDDQ35951586-404A914B-A9A7-459C-A344-BDC2B2B104EEQ36117791-790B6728-4F47-402E-B0E2-5161F2794BC6Q36521854-79808DD8-5A82-4AF0-9E51-E54AAE1415AFQ36689790-BA1A6995-D9C7-45B4-8728-70AF468A4C61Q37005060-2F368E24-47A5-4C39-A5AF-39872C5B97D9Q37009760-723C8A6E-60D2-4CB5-BB8F-0FBE133EB1ABQ37231130-BF0FD8D2-4888-48BC-A166-F2397EE7DBB3Q37364653-50DA66AB-B206-44D2-8AAC-4A37C74A1884Q40063998-85D33DC6-18B0-4CFB-A91C-5435DDFCC0FCQ40374056-391E73AF-DFF7-424F-879D-0E44B688360DQ41444373-ED4DFFD1-7BDA-42A1-9ADE-CD534852E6BDQ42852282-B70A4063-CF41-4D0E-BACE-40E343CF1281Q42881033-57DD85CF-036E-4327-910C-29708EA3B295Q42905792-0140019D-316C-488E-9723-905EF6A7BBF7Q44668352-B8DBF68B-84DD-4941-B963-A3A9F612239EQ46704590-388C3B19-1475-4330-9073-3A4EE553621BQ48371948-797C026F-201C-4746-A4F5-B1032BE3C177Q53058794-0C06A87B-36CA-47F4-80B9-63B15F387915
P2860
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@ast
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@en
type
label
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@ast
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@en
prefLabel
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@ast
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@en
P2093
P2860
P1433
P1476
Myelodysplasia and acute myelo ...... rituximab and interferon alpha
@en
P2093
Anne Marie Maddox
Armand Glassman
Elihu Estey
Felipe Samaniego
Fredrick B Hagemeister
H Alejandro Preti
Jorge Romaguera
Kimberly Hayes
Peter McLaughlin
P2860
P304
P356
10.1182/BLOOD-2004-08-3035
P407
P577
2005-03-01T00:00:00Z